We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New therapies in sickle cell disease.
- Authors
Vichinsky, Elliott
- Abstract
New therapies have evolved from our improved understanding of the biology of sickle cell disease (SCD) and the availability of a useful transgenic animal model. Several therapeutic options are available that interrupt the sickling process at various key pathways. Nitric oxide (NO)is a critical factor in the pathophysiology of SCD and is a promising antisickling agent with vasodilation properties. NO regulates blood vessel tone, endothelial adhesion, and the severity of ischaemia-reperfusion injury and anaemia in SCD. Although NO is difficult to administer, its precursor, L-arginine, is an oral supplement.
- Publication
Lancet (London, England), 2002, Vol 360, Issue 9333, p629
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(02)09776-3